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Sir,
With much interest we read the paper by Antoniou and
colleagues (British Journal of Cancer, October 18, p 1580). These
researchers described the development of a genetic model for
familial breast cancer, named BOADICEA, which takes into
account the simultaneous effects of BRCA1, BRCA2 and other
genes. There is a considerable need for such predictions for
purposes of management of women referred to genetic clinics and
for the considerations of eligibility of any prophylactic interven-
tions in both the clinical and research settings.
The BOADICEA model requires a computer program for risk
estimation, which is not easy to use in clinical practice. Moreover,
such a model is mostly hard to understand for clinicians.
Understandable risk estimation should, however, be available to
clinicians, so that they know what they are actually doing while
estimating disease risks. Our concern about this aspect of the
BOADICEA model was illustrated in Figure 3. The authors
presented a woman aged 40 years and unaffected with cancer.
Her mother and maternal aunt developed ovarian cancer and two
other maternal aunts developed breast cancer before the age of 50
years. This family is a good example of a typical Hereditary Breast
and Ovarian Cancer (HBOC) family. The risk for breast cancer in
these families is increased because of the combination of both
breast and ovarian cancers in the family, which highly points to
BRCA1 mutations. The BRCA1 mutation probability as predicted
by the BOADICEA model is high, 40.9%. The model then predicted
her risk of breast cancer at only 13%. For a clinician, this risk
estimation is hard to understand and feels illogical. It seems that in
the risk prediction by Antoniou et al (2004) the presence of
ovarian cancer is not important for the estimation of the
breast cancer risk for this woman. The authors did not discuss
this point.
Recently, Jonker et al (2003) have published a genetic model to
predict someone’s breast cancer risk based on the family history of
breast and ovarian cancer. This model can be considered as an
extension of the Claus model combined with the BRCAPRO model
(Claus et al, 1991; Parmigiani et al, 1998). In the Jonker et al
model, the familial clustering of breast and ovarian cancer is
explained by three genes, BRCA1, BRCA2 and a hypothetical third
gene BRCAu. This third gene was modelled to explain all familial
clustering of breast cancer unaccounted for by the BRCA1 and
BRCA2 genes. The model parameters were estimated using
published estimates of population incidence and relative risks.
As well as the BOADICEA model, the Jonker et al model is
not easy to use in clinical practice. For this reason, we extended
the easy-to-use Claus tables into the ‘Claus plus method’
based on the Jonker model (Claus et al, 1994; Van Asperen et al,
2004). Our method uses the Claus tables, but also incorporates
information on the presence of ovarian cancer, bilateral breast
cancer and whether there are more than two affected relatives. The
formula we obtained simplifies risk estimation in familial breast
cancer:
0:08 þ 0:40 ClausTable þ 0:07 ovariancancer
þ 0:08 bilateralbreastcancer þ 0:07 multiplecases:
The formula starts with an intercept of 0.08. This is the population
risk for breast cancer and the basis for further risk estimation. The
value of the Claus table should be multiplied by 0.4. The formula
subsequently includes the information on ovarian cancer, bilateral
breast cancer and more than two affected relatives. These
characteristics in the formula are one or zero. This new method
might offer a good alternative for breast cancer risk estimation in
clinical practice. The ‘Claus plus method’ is an easy applicable
method for hand-written pedigrees and at the moment it is
widely used in the Dutch cancer clinics. Based on the ‘Claus plus
method’, the predicted risk of breast cancer of the 40-year-old
woman in Figure 3 in the Antoniou paper was 31%. Although we
are still working on the validation of our method, this risk figure is
more in agreement with the risks as observed in typical HBOC
families.
The authors have mentioned several improvements to be made
for their multi-purpose BOADICEA model like genotype-specific
incidence rates, risk for other cancers and allele frequencies.
Besides this, we would like to recommend paying attention to the
applicability for clinical practice. To attain full development for the
BOADICEA model, the authors should be in close contact with the
ultimate users in clinical practice.
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Sir,
The BOADICEA model of genetic susceptibility to breast and
ovarian cancer was developed using complex segregation analysis
of breast and ovarian cancer (Antoniou et al, 2002, 2004). We agree
with van Asperen et al that as it stands, the model is not easy to use
in clinical practice. However, the model is currently being
implemented in web-based software that will provide a user-
friendly tool for clinical geneticists and oncologists. We disagree
however with the premise that the model is particularly hard to
understand. The BOADICEA model incorporates the effects of
BRCA1, BRCA2 and other genes. Although it has more risk
parameters than some other models, it is conceptually quite
similar to the Claus et al (1991) or BRCAPRO models (Parmigiani
et al, 1998), or the model proposed by Jonker et al (2003). The
major difference is the incorporation of a polygenic component to
explain familial aggregation of breast cancer not attributable to
BRCA1 and BRCA2.
van Asperen et al question the low breast cancer risk (13% by
age 70) estimated for the index woman in Figure 3 of our paper.
We agree that this estimate is probably anomalously low, due to
imprecision in the BRCA1 and BRCA2 penetrance estimates we
used. The average risk of breast cancer in BRCA1 mutation carriers
in the first version of the BOADICEA model was estimated to be
35% by age 70 (Antoniou et al, 2002), which is much lower than the
estimates used in the Jonker et al (2003). However, the BRCA1 and
BRCA2 incidence rates used in the first version of BOADICEA were
based on relatively small numbers of BRCA1 and BRCA2 mutation
positive families (62 in total) and may therefore be imprecise.
To improve the risk prediction, we have recently refitted the
BOADICEA model using additional data from two UK population-
based studies of breast cancer (Peto et al, 1999; Lalloo et al, 2003)
and data from the meta-analysis of the families of BRCA1/2
carriers identified through population-based studies of breast and
ovarian cancer (Antoniou et al, 2003). The updated data set
includes more than 500 BRCA1 and BRCA2 mutation positive
families, and therefore the incidence rates are estimated more
reliably (manuscript in preparation). In the updated version, the
average risk of breast cancer in BRCA1 mutation carriers by age 70
varies between 50 and 59% depending on the year of birth.
Applying the latest version of the model to the family in Figure 2 of
Antoniou et al (2004), the 40-year-old woman is predicted to carry
a BRCA1 mutation with probability 41% and a BRCA2 mutation
with a probability 1% (very similar to the previous estimates).
However, her predicted risk of developing breast cancer by age 70
is now higher, 28%, perhaps closer to the expectations of van
Asperen and co-workers.
van Asperen et al question the fact that the presence of ovarian
cancer in the family does not affect the breast risk. It is a feature
common to BOADICEA and all the other risk prediction models,
however, that the risks of breast and ovarian cancer in a family are
assumed to be independent given the BRCA1 and BRCA2
genotypes. Thus, the presence of ovarian cancer in the family
only affects the breast cancer risk in so far as it affects the BRCA1
and BRCA2 carrier probabilities.
We agree that the regression model of van Asperen et al (2004)
can be more easily used in clinical practice. However, this model
cannot deal with the complex family histories seen in genetic
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the independent variables on the predictions given the Jonker et al
(2003) model. Therefore, the validity of the regression formula
critically depends on an as yet (to our knowledge) unvalidated
model. In any event, evaluation of the accuracy of any model in
predicting the correct carrier and cancer risks should be based on
validation studies in independent series and not on the basis of
individual families.
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